Investors

NASDAQ: STEM

Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.

Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for spinal cord injury (SCI) and age-related macular degeneration (AMD). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product. More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Letter to Investors
January 2015  Letter to Investors from CEO Martin McGlynn
Recent News
07/23/15Court Rules That StemCells, Inc. Lacks Standing to Pursue Patent Infringement Suit
NEWARK, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that the Company's patent infringement case, StemCells, Inc. v. Neuralstem, Inc., has been dismissed by the U.S. Federal District Court for the District of Maryland for lack of standing. The judge's decision was based solely on the grounds that a former associate of ... 
Printer Friendly Version
07/22/15StemCells, Inc. Announces Webcast to Discuss Second Quarter 2015 Financial Results
NEWARK, Calf., July 22, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter 2015, after the market close on Thursday, August 6. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Ti... 
Printer Friendly Version
07/20/15StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration
Radiant(TM) Study is the First Controlled Phase II Trial to Investigate the Efficacy of Human Neural Stem Cells for the Treatment of Dry AMD NEWARK, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the brain, eye and spine, announced today that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The ... 
Printer Friendly Version
07/09/15StemCells, Inc. Clinical Programs Overview and Progress Update
Video Available of Presentation Made to World-Leading Scientists and Clinicians at the International Society for Stem Cell Research (ISSCR) NEWARK, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), in cooperation with the International Society for Stem Cell Research (ISSCR), has posted a video of the presentation made by the Company's vice president of clinical research and chief medical officer Dr. Stephen Huhn, at the ISSCR 2015 Annual Meeting. Held last month in Stockho... 
Printer Friendly Version
More >>
Upcoming Events
DateTitle
08/06/15
Q2 2015 StemCells, Inc. Earnings Conference Call
Presentations
DateTitle
03/19/15
Download Documentation StemCells, Inc. at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.42
Change (%) Stock is Down 0.01 (2.33%)
Volume438,993
Data as of 08/04/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet